Interpreting CRISPR Screens Through Protein-Level Biology
Amanda McQuade and Nathaniel Robichaud discuss how integrated proteomic and transcriptomic profiling can reveal cellular responses to genetic perturbations that are not captured through RNA analysis alone.
Functional genomics and CRISPR perturbation screens have become important tools for investigating gene function and identifying disease-relevant biology. While transcriptomic profiling provides valuable insight into cellular responses to genetic perturbations, RNA measurements alone may not fully capture downstream biological processes such as protein activation, secretion, and post-translational regulation. Integrating protein-level measurements with transcriptomic analysis can provide a more comprehensive view of cellular phenotypes and molecular mechanisms.
In this webinar, Amanda McQuade, PhD (Kampmann Lab, University of California, San Francisco), and Nathaniel Robichaud, PhD (Nomic Bio), will discuss how integrated proteomic profiling can complement transcriptomic analysis in CRISPR screening workflows. The session will examine the use of CRISPR interference (CRISPRi) screening to identify transcriptional and epigenetic regulators of disease-associated microglial activation states, as well as approaches to characterize cellular phenotypes detectable primarily by protein-level measurements. The discussion will also highlight how combined transcriptomic and proteomic datasets support target validation and prioritization in discovery biology research.
Interpreting CRISPR Screens Through Protein-Level Biology
Subscribe to Updates
Get the latest insights and updates delivered straight to your inbox weekly.
Functional genomics and CRISPR perturbation screens have become important tools for investigating gene function and identifying disease-relevant biology. While transcriptomic profiling provides valuable insight into cellular responses to genetic perturbations, RNA measurements alone may not fully capture downstream biological processes such as protein activation, secretion, and post-translational regulation. Integrating protein-level measurements with transcriptomic analysis can provide a more comprehensive view of cellular phenotypes and molecular mechanisms.
In this webinar, Amanda McQuade, PhD (Kampmann Lab, University of California, San Francisco), and Nathaniel Robichaud, PhD (Nomic Bio), will discuss how integrated proteomic profiling can complement transcriptomic analysis in CRISPR screening workflows. The session will examine the use of CRISPR interference (CRISPRi) screening to identify transcriptional and epigenetic regulators of disease-associated microglial activation states, as well as approaches to characterize cellular phenotypes detectable primarily by protein-level measurements. The discussion will also highlight how combined transcriptomic and proteomic datasets support target validation and prioritization in discovery biology research.
Functional genomics and CRISPR perturbation screens have become important tools for investigating gene function and identifying disease-relevant biology. While transcriptomic profiling provides valuable insight into cellular responses to genetic perturbations, RNA measurements alone may not fully capture downstream biological processes such as protein activation, secretion, and post-translational regulation. Integrating protein-level measurements with transcriptomic analysis can provide a more comprehensive view of cellular phenotypes and molecular mechanisms.
In this webinar, Amanda McQuade, PhD (Kampmann Lab, University of California, San Francisco), and Nathaniel Robichaud, PhD (Nomic Bio), will discuss how integrated proteomic profiling can complement transcriptomic analysis in CRISPR screening workflows. The session will examine the use of CRISPR interference (CRISPRi) screening to identify transcriptional and epigenetic regulators of disease-associated microglial activation states, as well as approaches to characterize cellular phenotypes detectable primarily by protein-level measurements. The discussion will also highlight how combined transcriptomic and proteomic datasets support target validation and prioritization in discovery biology research.
Interpreting CRISPR Screens Through Protein-Level Biology
Functional genomics and CRISPR perturbation screens have become important tools for investigating gene function and identifying disease-relevant biology. While transcriptomic profiling provides valuable insight into cellular responses to genetic perturbations, RNA measurements alone may not fully capture downstream biological processes such as protein activation, secretion, and post-translational regulation. Integrating protein-level measurements with transcriptomic analysis can provide a more comprehensive view of cellular phenotypes and molecular mechanisms.
In this webinar, Amanda McQuade, PhD (Kampmann Lab, University of California, San Francisco), and Nathaniel Robichaud, PhD (Nomic Bio), will discuss how integrated proteomic profiling can complement transcriptomic analysis in CRISPR screening workflows. The session will examine the use of CRISPR interference (CRISPRi) screening to identify transcriptional and epigenetic regulators of disease-associated microglial activation states, as well as approaches to characterize cellular phenotypes detectable primarily by protein-level measurements. The discussion will also highlight how combined transcriptomic and proteomic datasets support target validation and prioritization in discovery biology research.
Watch Now
Interpreting CRISPR Screens Through Protein-Level Biology
Functional genomics and CRISPR perturbation screens have become important tools for investigating gene function and identifying disease-relevant biology. While transcriptomic profiling provides valuable insight into cellular responses to genetic perturbations, RNA measurements alone may not fully capture downstream biological processes such as protein activation, secretion, and post-translational regulation. Integrating protein-level measurements with transcriptomic analysis can provide a more comprehensive view of cellular phenotypes and molecular mechanisms.
In this webinar, Amanda McQuade, PhD (Kampmann Lab, University of California, San Francisco), and Nathaniel Robichaud, PhD (Nomic Bio), will discuss how integrated proteomic profiling can complement transcriptomic analysis in CRISPR screening workflows. The session will examine the use of CRISPR interference (CRISPRi) screening to identify transcriptional and epigenetic regulators of disease-associated microglial activation states, as well as approaches to characterize cellular phenotypes detectable primarily by protein-level measurements. The discussion will also highlight how combined transcriptomic and proteomic datasets support target validation and prioritization in discovery biology research.
Download resource
Get the latest insights and updates delivered straight to your inbox weekly.
Interpreting CRISPR Screens Through Protein-Level Biology
Get the latest insights and updates delivered straight to your inbox weekly.
Functional genomics and CRISPR perturbation screens have become important tools for investigating gene function and identifying disease-relevant biology. While transcriptomic profiling provides valuable insight into cellular responses to genetic perturbations, RNA measurements alone may not fully capture downstream biological processes such as protein activation, secretion, and post-translational regulation. Integrating protein-level measurements with transcriptomic analysis can provide a more comprehensive view of cellular phenotypes and molecular mechanisms.
In this webinar, Amanda McQuade, PhD (Kampmann Lab, University of California, San Francisco), and Nathaniel Robichaud, PhD (Nomic Bio), will discuss how integrated proteomic profiling can complement transcriptomic analysis in CRISPR screening workflows. The session will examine the use of CRISPR interference (CRISPRi) screening to identify transcriptional and epigenetic regulators of disease-associated microglial activation states, as well as approaches to characterize cellular phenotypes detectable primarily by protein-level measurements. The discussion will also highlight how combined transcriptomic and proteomic datasets support target validation and prioritization in discovery biology research.